November 22
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we are
A clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectMelbourne Health’s research vision is to be a leading centre for to delivery of translational health, research and education.
ViewThe Telethon Kids Institute is the largest research institute in Western Australia, with a bold vision to improve the health and development of children through excellence in research. Focused on translation, the Institute’s researchers and clinicians work closely, together with our research collaborators across Australia and around the world, to maximise research impact. They have extensive experience in coordinating technology and pharmaceutical interventions – including industry-sponsored trials – across a variety of diseases affecting children
ViewThe Walter and Eliza Hall Institute is the oldest medical research institute in Australia and will celebrate its centenary in 2015.
The institute is affiliated with The University of Melbourne and The Royal Melbourne Hospital and offers postgraduate training as the Department of Medical Biology of The University of Melbourne.
Brandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
Read moreAzura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
Read more